Abstracts tagged "juvenile idiopathic arthritis (JIA) and prescribing trends"

Abstract Number: 1228 • 2016 ACR/ARHP Annual Meeting
Prescribing for Children with Rheumatologic Disease: Differences Between Pediatric and Adult Rheumatologists
Heather Van Mater¹, Stephen Balevic², Gary Freed³ and Sarah J. Clark⁴, ¹Pediatrics/ Pediatric Rheumatology, Duke University Medical Center, Durham, NC, ²Rheumatology/Pediatric Rheumatology, Duke University Medical Center, Durham, NC, ³University of Michigan Health System, Ann Arbor, MI, ⁴Pediatrics & Communicable Diseases, University of Michigan Health System, Ann Arbor, MI
Background/Purpose: Rheumatologic diseases affect 300,000 children in the United States and are associated with significant morbidity.1,2 Due to a national shortage of pediatric rheumatologists (PR),2…
Abstract Number: 1145 • 2012 ACR/ARHP Annual Meeting
Use of Non-Etanercept Biologics in Children with Juvenile Idiopathic Arthritis: Results From the Biologics for Children with Rheumatic Diseases Study
Lianne Kearsley-Fleet¹, Eileen Baildam², Michael Beresford³, Rebecca Davies⁴, Helen E. Foster⁵, Katy Mowbray¹, Taunton R. Southwood⁶, Wendy Thomson¹ and Kimme L. Hyrich⁷, ¹Arthritis Research UK Epidemiology Unit, Manchester Academic Health Science Centre, Manchester, United Kingdom, ²Paediatric Rheumatology, Alder Hey Children's Foundation NHS Trust, Liverpool, United Kingdom, ³University of Liverpool, Institute of Translational Medicine (Child Health), Alder Hey Children's Foundation NHS Trust, Liverpool, United Kingdom, ⁴Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, ⁵Institute Cellular Medicine, Musculoskeletal Research Group, Newcastle upon Tyne, United Kingdom, ⁶Institute of Child Health, University of Birmingham and Birmingham Children's Hospital, Birmingham, United Kingdom, ⁷Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom
Background/Purpose: The management of juvenile idiopathic arthritis (JIA) has been revolutionised by the introduction of biologic therapy, although the majority remain unlicensed for children. Until…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].